

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 405/12, A61P 25/00, A61K 31/205, 31/19		A1	(11) International Publication Number: WO 00/35910
			(43) International Publication Date: 22 June 2000 (22.06.00)
(21) International Application Number: PCT/GB99/04176 (22) International Filing Date: 10 December 1999 (10.12.99) (30) Priority Data: 9827431.9 11 December 1998 (11.12.98) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): JONES, David, Alan [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). (74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intel- lectual Property, Two New Horizons Court, Brentford, Mid- dlesex TW8 9EP (GB).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: DERIVATIVE OF PAROXETINE

(57) Abstract

Compounds of
Formula (1) and alkali
metal and amine and acid
addition salts thereof are
useful in the treatment of
CNS disorders.



(1)


DERIVATIVE OF PAROXETINE

The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders. In particular the present invention relates to a novel derivative of paroxetine.

Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (-)-*trans* isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxyphenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of *inter alia* depression, obsessive compulsive disorder (OCD) and panic.

This invention relates to a novel derivative of paroxetine.

According to the present invention there is provided a compound of formula (1)



(2-[(3*S*,4*R*)-*trans*-4-(4'-fluorophenyl)-3-(3'',4''-methylenedioxyphenoxymethyl)piperidin-1-yl]butan-1,4-dioic acid)

The compound of this invention may exist in the free acid form as shown in formula (1) or as the corresponding zwitterion. Both forms are part of this invention.

The compound of formula (1) may also exist as salts for example with alkali metals or amines, or addition salts with strong acids.

Suitable salts include those with alkali metals, preferably sodium, potassium or lithium, or with a mineral acid, for example hydrochloric acid, or sulphonic acid. Amine salts may include salts with paroxetine itself. Also the compound of formula (1) may exist as a mono- or di-salt, or as a mixed salt.

5

A particularly important salt is the 1:1 (by mole) salt with paroxetine.

Compounds of structure (1) have a chiral centre on the piperidine nitrogen substituent as well as the two chiral centres on the piperidine ring, so may exist in two forms. These forms may be separated by crystallisation or chromatography, optionally in the form of a salt, for example a salt with an optically active base.

10

15

The individual isomers, and mixtures thereof, of the compounds of formula (1) and the above described salts are all within the scope of this invention.

The present invention also provides a method for the preparation of compounds of formula (1) by the addition reaction of paroxetine (as the free base) to maleic acid. The procedure may be carried out at elevated temperature in an appropriate solvent.

20

Among solvents suitable for the addition reaction are polar aprotic solvents, for example N,N-dimethylformamide, alcohols such as ethanol and isopropanol, and esters such as ethyl acetate, and hydrocarbons such as toluene.

25

The reaction of paroxetine with maleic acid tends to result in the recovery of the paroxetine salt of the compound of formula (1) rather than the free acid. Accordingly the free acid is suitably obtained by preparing the salt and treating the salt to recover the acid.

30

The paroxetine salt of compound (1) may conveniently be prepared by contacting paroxetine free base with maleic acid in a suitable solvent, for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C. The paroxetine salt of compound (1) may be isolated by crystallisation, and may be purified by a hot slurry, for example at reflux temperature in an appropriate solvent, for example an ester such as ethyl acetate, an alcohol such as propan-2-ol, or a ketone such as acetone.

35

The paroxetine salt of compound (1) may also be prepared from paroxetine maleate (1:1) salt by heating in an appropriate solvent, preferably butan-2-ol. Compound (1) may be isolated from its paroxetine salt by acidification with 1 equivalent of acid, for example hydrochloric acid. Hence compound (1) may be prepared by addition of 1 molar equivalent of hydrogen chloride in propan-2-ol to a suspension of the paroxetine salt of compound (1) in propan-2-ol with or without heating, and isolated as the free acid by crystallisation from the reaction medium by the addition of water and acetone. Alternatively, compound (1) free acid may be prepared from the isolated paroxetine salt by treatment with 1 equivalent of hydrochloric acid in acetone followed by crystallisation from the medium.

Alternatively, neutralisation of the paroxetine salt of compound (1) with 1 molar equivalent of an acid such as hydrochloric acid followed by evaporation or lyophilisation, produces a solid mixture of the salt of paroxetine with the acid, for example paroxetine hydrochloride, and compound (1), and this two component pharmaceutical salt is also included within the scope of this invention.

Other salts of compound (1), for example mono sodium or mono lithium salts may be prepared by reaction of compound (1) with 1 equivalent of base, for example sodium or lithium hydroxide respectively.

Another class of salts of compound (1) may be formed by reaction with 2 equivalents of strong base, such as for example the disodium or dipotassium salt.

Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Maleic acid is commercially available.

Compound (1) and its salts of this invention are anticipated to be useful to treat and prevent the following disorders:

Alcoholism

Depression

Panic Disorder

Obesity

Migraine

Anorexia

Pre-Menstrual Syndrome (PMS)

Trichotillomania

Anxiety

Obsessive Compulsive Disorder

Chronic Pain

Senile Dementia

Bulimia

Social Phobia

Adolescent Depression

Dysthymia

Substance Abuse

These disorders are hereinafter referred to as "the Disorders".

- 5 Accordingly, the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a compound of the invention to a sufferer in need thereof.

- 10 The present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises an admixture of a compound of the invention with a pharmaceutically acceptable carrier.

The present invention also provides the use of a compound of the invention for treating and/or preventing any one or more of the Disorders.

- 15 The present invention also provides the use of a compound of the invention in the manufacture of a medicament for treating and/or preventing any one or more of the Disorders.

- 20 Most suitably the present invention is applied to the treatment of depression, OCD and panic.

- 25 Compositions containing a compound of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine derivative or salt.

- 30 The medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

- 35 The composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to 100mg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg

of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.

Preferred unit dosage forms include tablets or capsules.

5

The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.

10

Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilised in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.

15

Specific examples of pharmaceutical compositions include those described EP-B-0223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.

The following Examples illustrate the invention.

20

Example 1

25

A mixture of paroxetine base and maleic acid (0.5 mole equivalents) in ethyl acetate (5 volumes) was stirred and heated to reflux to give a clear solution, then cooled to room temperature. The crystalline solid which formed was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1-N-(3S,4R)-trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxyethylphenoxyethyl] piperidinyl butandioic acid as the paroxetine salt.

30

Example 2

35

N-phenyloxycarbonyl paroxetine (5.0 kg), potassium hydroxide flake (4.5 kg) and toluene (75.0 litres) were heated to reflux under a nitrogen atmosphere. After stirring for 4 hours at reflux the contents of the reactor were allowed to cool to room temperature. Water (50 litres) was added and the mixture stirred for 30 minutes and then allowed to settle. The lower aqueous layer was drained from the reactor and the toluene layer heated to reflux and dried in a Dean and Stark apparatus. Toluene (10 litres) was added and approximately 10 litres of the solvent was removed by distillation. The remaining solution was cooled to

approximately 90-95°C and solid maleic acid (1.04 kg) was added with vigorous stirring. The temperature was held at 40°C for two hours to allow for the bulk of the crystallisation to occur, then the product was filtered and dried to give 1-N-(3S,4R)-trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxyethylphenoxymethyl] piperidiny butandioic acid (3.7 kg, approximately 30% pure).

A portion of this solid (340 g) was suspended in ethyl acetate (1.5 litres) and heated at reflux for 1 hour. The suspension was cooled slightly and the solid collected by filtration. The solid was washed with ethyl acetate and dried under vacuum to give 50.56g of pure 1-N-(3S,4R)-trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxyethylphenoxymethyl] piperidiny butandioic acid as the 1:1 paroxetine salt, as a white crystalline solid.

Characterisation:

15

IR (ν_{\max} cm⁻¹) 1608, 1512, 1376, 1298, 1234, 1181, 1143, 1106, 1033, 930, 831, 780, 721, 542.

MS (positive ion electrospray) 330 (M+H)⁺ (100%), 446 (M+H)⁺ (15%)
(negative ion electrospray) 889 (2M-H)⁺ (100%).

20 Melting point 185-191°C.

Example 3.

Preparation of 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxyethylphenoxymethyl] piperidiny butandioic acid paroxetine salt.

25

Maleic acid (0.176 g) was added to a solution of paroxetine free base (0.5 g) in toluene at 90-95°C with rapid stirring. The reaction mixture was stirred at this temperature for 1 hour then cooled to 40-50°C and the crystalline product that formed isolated by filtration. The solid was re-suspended in hot ethyl acetate and stirred for 1 hour. The hot suspension was filtered to give the title compound as a white solid.

30

Example 4

35 Preparation of 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxyethylphenoxymethyl] piperidiny butandioic acid.

A suspension of 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxy-methyloxymethyl] piperidinyl butandioic acid paroxetine salt (5.06 g) in propan-2-ol (50 ml) was treated with a solution of hydrogen chloride in propan-2-ol (6N, 1.3 ml). The reaction mixture was briefly heated to reflux to
5 form a clear solution, then cooled to room temperature, diluted with acetone (5 ml) and then water (150 ml). The resulting cloudy solution was stirred and scratched to induce crystallisation. Filtration and drying gave the title compound as a white crystalline solid (1.43 g).

10 Characterisation:


MS (positive ion electrospray) 330 (M+H)⁺ (90%), 446 (M+H)⁺ (100%).
(negative ion electrospray) 444 (M-H)⁻ (60%), 889 (2M-H)⁻ (100%).

15 Example 5

A stirred suspension of 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxy-methyloxymethyl] piperidinyl butandioic acid 1:1 paroxetine salt (2.60 g) in acetone (50 ml) was treated with a solution of aqueous hydrochloric
20 acid (0.5 ml, 5 molar) and the mixture was stirred vigorously at room temperature. Water (15 ml) was added to give a cloudy solution which was seeded with 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxy-methyloxymethyl] piperidinyl butandioic acid. Further stirring and scratching induced crystallisation of 1-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxy-methyloxymethyl]
25 piperidinyl butandioic acid as a white crystalline solid (0.62 g).

CLAIMS

1. A compound of formula (1)



5

2. A compound of claim 1 in the form of an alkali metal salt, an amine salt or an acid addition salt.
- 10 3. A compound of claim 1 in the form of the paroxetine salt thereof.
4. A compound of claim 1 in the form of the hydrochloride salt thereof.
- 15 5. A solid blend of a compound according to any preceding claim and paroxetine hydrochloride.
6. A process for preparing a compound according to any preceding claim, which comprises reacting paroxetine in solution with maleic acid.
- 20 7. A process for preparing a blend of claim 5 which comprises treating a compound of claim 3 with hydrochloric acid.
8. A method of treating the Disorders which comprises administering to a
- 25 patient in need thereof an effective amount of a compound according to any one of claims 1 to 5 or prepared using the process of claim 6 or 7.
9. A pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises a compound according to any one of claims 1 to

5 or prepared using the process of claim 6 or 7, together with a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

Int: lonal Application No
PCT/GB 99/04176

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 98 56787 A (SYNTHON B V) 17 December 1998 (1998-12-17) see the claims page 7, line 10 - line 15 page 17, line 10; table 6 ----	1,6-9
P,X	WO 99 52901 A (MAN JOHN ;JACEWICZ VICTOR WITOLD (GB); JONES ALAN DAVID (GB); SMIT) 21 October 1999 (1999-10-21) page 7, line 25 -page 14, line 9 ----	1,6-9
P,X	WO 99 40084 A (CROWE DAVID ;KEEFFE DEIRDRE O (GB); SMITHKLINE BEECHAM PLC (GB); U) 12 August 1999 (1999-08-12) page 4, line 15 - line 26 -----	1,6-9